Abdera: optimizing tunable radiotherapeutics for safety

Abdera believes its approach to creating tunable radiotherapeutics will allow it to reach a broader range of targets than others can address while avoiding the main types of toxicity associated with the modality.

Emerging from stealth mode on Thursday with $142 million across two rounds of funding, Abdera Therapeutics Inc. is developing a lead program targeting DLL3 built from its Radio Optimized Vector Engineering (ROVEr) platform, which includes custom-built antibodies with engineered Fc domains for optimized pharmacokinetics...